Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Sponsor: Oncolytics Biotech
A PHASE1 clinical study on Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by Oncolytics Biotech and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oncolytics Biotech
For direct contact, visit the study record on ClinicalTrials.gov .